Cumberland Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Phase II FIGHT DMD data showed a 5.4-point ejection-fraction difference for high-dose ifetroban versus placebo plus matched natural-history controls. FDA granted rolling review, and an NDA is planned alongside ongoing phase II programs in other indications.
-
A major strategic transaction provided $100M in cash, enabling a pivot to clinical development and a special $1.50/share dividend. The company now focuses on advancing ifetroban programs in rare diseases, with strong financial reserves and multiple clinical milestones expected in 2026.
-
Q1 2026 revenue rose 5% year-over-year (excluding a prior milestone), with positive cash flow and a net loss of $3.3 million. A $100 million Apotex deal will shift focus to pipeline innovation, while FDA approvals and new product launches drive momentum.
Fiscal Year 2025
-
2025 saw 18% revenue growth, improved adjusted earnings, and global expansion, led by Vibativ, Sancuso, and the launch of Talicia. The pipeline advanced with ifetroban's breakthrough results and new FDA designations, while 2026 targets continued double-digit growth.
-
Q3 revenue reached $8.3M, with year-to-date revenue up 12% to $30.9M. Expanded the portfolio with Talicia, launched Vibativ internationally, and advanced Ifetroban clinical programs. Cash flow from operations was $5M, and total assets stood at $66M.
-
Second Quarter 2025 revenue grew 10% year-over-year to $10.8 million, with strong gains from Vibativ, Sancuso, Kristalose, and Caldolor. Clinical pipeline advanced, including positive iFuture Phase II results and international Vibativ launches.
-
Q1 2025 revenue rose 38% year-over-year to $11.7M, with net profit of $1.3M and strong cash flow. Key milestones included Vibativ's China approval and positive phase II Ifetroban results in DMD. Growth is expected across brands and clinical programs.
Fiscal Year 2024
-
Delivered 11.6% Q4 revenue growth and advanced key brands and pipeline, including ifetroban for DMD. Expanded international reach, improved operating expenses, and expects double-digit revenue growth and positive cash flow in 2025.
-
Q3 2024 net revenue was $9.1M, with strong results from Kristalose and Sancuso, but Vibativ was impacted by hurricane-related disruptions. Gross margin improved to 85%, and new clinical data and product developments support future growth.
-
Q2 2024 net revenue rose 16% sequentially to $9.9M, with adjusted earnings of $0.2M and strong product growth from Kristalose, Vibativ, and Sancuso. Management remains optimistic for double-digit revenue growth and positive cash flow in 2024.